Pfizer now expects to produce 80 million courses of COVID-19 pill, CEO tells CNBC

  • In US
  • 2021-11-29 13:26:51Z
  • By Reuters

(Reuters) -Pfizer Inc now expects to manufacture 80 million treatment courses of its experimental COVID-19 antiviral drug, up from a previous forecast of 50 million, Chief Executive Officer Albert Bourla said in a CNBC interview on Monday.

Earlier this month, Pfizer said it expects to manufacture 180,000 treatment courses by the end of this year and at least 50 million courses by the end of next year, including 21 million in the first half of 2022.

"We can right now commit to 80 million doses ... thanks to our manufacturing machine," Bourla told CNBC.

Bourla said he was confident that the drug, with the brand name Paxlovid, would be unaffected by the Omicron variant of the coronavirus.

Adding that the company would know more details about the new variant in the next few weeks.

Pfizer applied for emergency authorization of Paxlovid last week after reporting data showing that it was 89% effective at preventing hospitalization or death in at-risk people.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Maju Samuel)


More Related News

Guest opinion:
Guest opinion: 'It has been a true privilege to serve as CEO of Healthcare Network'

Healthcare Network celebrates 45 years of serving the community this year.

Pfizer says it applied for Japan gov
Pfizer says it applied for Japan gov't approval for oral COVID-19 drug
  • US
  • 2022-01-14 02:40:59Z

TOKYO (Reuters) -U.S. drugmaker Pfizer Inc said on Friday it has applied for Japanese government approval for its oral COVID-19 treatment. The application...

Biogen seeks dialogue with U.S. CMS about Alzheimer
Biogen seeks dialogue with U.S. CMS about Alzheimer's drug coverage decision

In a draft decision on Tuesday, CMS, which runs the government health plan for people over age 65, said it would cover Aduhelm and similar treatments only for patients enrolled in approved clinical trials. Biogen's Japanese partner Eisai Co Ltd strongly opposed the draft decision, saying the proposal would severely restrict Medicare beneficiary access for the foreseeable future to all drugs in this class.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: US